In clinical trials, over 10% of patients experienced back pain, arthralgia, abdominal pain, and dyspepsiaFDA Label. Less commonly, patients experience angioedema, generalized rash, bullous skin reactions, iritis, and uveitisFDA Label.
Patients experiencing an overdose may experience a decrease in serum calcium and phosphorusFDA Label. Patients can be given milk or antacids to bind the drug and reduce its absorptionFDA Label. In more severe cases, patients may require gastric lavage and intravenous calciumFDA Label. A lethal dose in rats is equivalent to 320 to 620 times the human dose based on surface areaFDA Label.
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's diseaseFDA LabelA959,A203111. It functions by preventing resorption of boneFDA LabelA959.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pantoprazole | Pantoprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Omeprazole | Omeprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Lansoprazole | Lansoprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Esomeprazole | Esomeprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Rabeprazole | Rabeprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexlansoprazole | Dexlansoprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexrabeprazole | Dexrabeprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Ilaprazole | Ilaprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Deferasirox | The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Risedronic acid is combined with Deferasirox. |
| Olanzapine | Olanzapine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Cimetidine | Cimetidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Nizatidine | Nizatidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Ranitidine | Ranitidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Famotidine | Famotidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Methantheline | Methantheline can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Promethazine | Promethazine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Doxepin | Doxepin can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Asenapine | Asenapine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Metiamide | Metiamide can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Roxatidine acetate | Roxatidine acetate can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Lafutidine | Lafutidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Lavoltidine | Lavoltidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Niperotidine | Niperotidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Epinastine | Epinastine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Bevacizumab | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Risedronic acid. |
| Lenalidomide | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Risedronic acid. |
| Thalidomide | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Risedronic acid. |
| Sunitinib | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Risedronic acid. |
| Ranibizumab | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Risedronic acid. |
| Fumagillin | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Risedronic acid. |
| Resveratrol | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Risedronic acid. |
| Halofuginone | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Risedronic acid. |
| Anecortave acetate | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave acetate is combined with Risedronic acid. |
| Endostatin | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Risedronic acid. |
| Semaxanib | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Risedronic acid. |
| Squalamine | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Risedronic acid. |
| Pazopanib | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Risedronic acid. |
| Volociximab | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Volociximab is combined with Risedronic acid. |
| TNP-470 | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when TNP-470 is combined with Risedronic acid. |
| Pomalidomide | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Risedronic acid. |
| Roquinimex | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Risedronic acid. |
| Endostar | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostar is combined with Risedronic acid. |
| Trebananib | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Risedronic acid. |
| Anecortave | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Risedronic acid. |
| Beloranib | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Beloranib is combined with Risedronic acid. |
| Brolucizumab | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Risedronic acid. |
| Icosapent | The risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Risedronic acid. |
| Mesalazine | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mesalazine is combined with Risedronic acid. |
| Indomethacin | The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Risedronic acid. |
| Nabumetone | The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Risedronic acid. |
| Ketorolac | The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Risedronic acid. |
| Tenoxicam | The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Risedronic acid. |
| Celecoxib | The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Risedronic acid. |
| Tolmetin | The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Risedronic acid. |
| Rofecoxib | The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Risedronic acid. |
| Piroxicam | The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Risedronic acid. |
| Fenoprofen | The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Risedronic acid. |
| Valdecoxib | The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Risedronic acid. |
| Diclofenac | The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Risedronic acid. |
| Sulindac | The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Risedronic acid. |
| Flurbiprofen | The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Risedronic acid. |
| Etodolac | The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Risedronic acid. |
| Mefenamic acid | The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Risedronic acid. |
| Naproxen | The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Risedronic acid. |
| Sulfasalazine | The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Risedronic acid. |
| Phenylbutazone | The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Risedronic acid. |
| Meloxicam | The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Risedronic acid. |
| Carprofen | The risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Risedronic acid. |
| Diflunisal | The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Risedronic acid. |
| Salicylic acid | The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Risedronic acid. |
| Meclofenamic acid | The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Risedronic acid. |
| Acetylsalicylic acid | The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Risedronic acid. |
| Oxaprozin | The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Risedronic acid. |
| Ketoprofen | The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Risedronic acid. |
| Balsalazide | The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Risedronic acid. |
| Ibuprofen | The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Risedronic acid. |
| Olsalazine | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Olsalazine is combined with Risedronic acid. |
| Lumiracoxib | The risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Risedronic acid. |
| Magnesium salicylate | The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Risedronic acid. |
| Salsalate | The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Risedronic acid. |
| Choline magnesium trisalicylate | The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Risedronic acid. |
| Antrafenine | The risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Risedronic acid. |
| Aminophenazone | The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Risedronic acid. |
| Antipyrine | The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Risedronic acid. |
| Tiaprofenic acid | The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Risedronic acid. |
| Etoricoxib | The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Risedronic acid. |
| Taxifolin | The risk or severity of gastrointestinal bleeding can be increased when Taxifolin is combined with Risedronic acid. |
| Oxyphenbutazone | The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Risedronic acid. |
| Licofelone | The risk or severity of gastrointestinal bleeding can be increased when Licofelone is combined with Risedronic acid. |
| Nimesulide | The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Risedronic acid. |
| Benoxaprofen | The risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Risedronic acid. |
| Metamizole | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Metamizole is combined with Risedronic acid. |
| Zomepirac | The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Risedronic acid. |
| Cimicoxib | The risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Risedronic acid. |
| Lornoxicam | The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Risedronic acid. |
| Aceclofenac | The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Risedronic acid. |
| Zaltoprofen | The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Risedronic acid. |
| Azapropazone | The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Risedronic acid. |
| Parecoxib | The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Risedronic acid. |
| Salicylamide | The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Risedronic acid. |